Top-Rated StocksTop-RatedNASDAQ:DMRA Damora Therapeutics, Inc. Common Stock (DMRA) Stock Price, News & Analysis $22.05 -1.20 (-5.16%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Damora Therapeutics, Inc. Common Stock Stock (NASDAQ:DMRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get DMRA alerts:Sign Up Key Stats Today's Range$21.83▼$23.0550-Day Range$18.43▼$30.0652-Week Range$15.76▼$38.33Volume671,091 shsAverage Volume435,675 shsMarket Capitalization$1.37 billionP/E RatioN/ADividend YieldN/APrice Target$46.38Consensus RatingBuy Company Overview Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark. Read More Damora Therapeutics, Inc. Common Stock Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreDMRA MarketRank™: 3.098471986415 of 5 starsDamora Therapeutics, Inc. Common Stock scored higher than 62% of companies evaluated by MarketBeat, and ranked 340th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingBuy Consensus RatingDamora Therapeutics, Inc. Common Stock has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialDamora Therapeutics, Inc. Common Stock has a consensus price target of $46.38, representing about 110.3% upside from its current price of $22.05.Amount of Analyst CoverageDamora Therapeutics, Inc. Common Stock has only been the subject of 4 research reports in the past 90 days.Read more about Damora Therapeutics, Inc. Common Stock's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Damora Therapeutics, Inc. Common Stock are expected to decrease in the coming year, from ($2.09) to ($2.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Damora Therapeutics, Inc. Common Stock is -15.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Damora Therapeutics, Inc. Common Stock is -15.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDamora Therapeutics, Inc. Common Stock has a P/B Ratio of 3.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.61% of the float of Damora Therapeutics, Inc. Common Stock has been sold short.Short Interest Ratio / Days to CoverDamora Therapeutics, Inc. Common Stock has a short interest ratio ("days to cover") of 10.66, which indicates bearish sentiment.Change versus previous monthShort interest in Damora Therapeutics, Inc. Common Stock has recently decreased by 8.98%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDamora Therapeutics, Inc. Common Stock does not currently pay a dividend.Dividend GrowthDamora Therapeutics, Inc. Common Stock does not have a long track record of dividend growth. News and Social Media1.8 / 5News Sentiment-0.13 News SentimentDamora Therapeutics, Inc. Common Stock has a news sentiment score of -0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Damora Therapeutics, Inc. Common Stock this week, compared to 3 articles on an average week.MarketBeat Follows2 people have added Damora Therapeutics, Inc. Common Stock to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership3.0 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $252,875.00 in company stock, which represents 0.0185% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Damora Therapeutics, Inc. Common Stock insiders have bought more of their company's stock than they have sold. Specifically, they have bought $252,875.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders0.40% of the stock of Damora Therapeutics, Inc. Common Stock is held by insiders.Percentage Held by Institutions14.20% of the stock of Damora Therapeutics, Inc. Common Stock is held by institutions.Read more about Damora Therapeutics, Inc. Common Stock's insider trading history. Receive DMRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Damora Therapeutics, Inc. Common Stock and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DMRA Stock News HeadlinesWhat is HC Wainwright's Estimate for DMRA FY2026 Earnings?November 9 at 1:29 AM | americanbankingnews.comGuggenheim Initiates Coverage on Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)November 8, 2026 | americanbankingnews.comTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.November 12 at 1:00 AM | Base Camp Trading (Ad)Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Crosses Above Fifty Day Moving Average After Analyst DowngradeNovember 8, 2026 | americanbankingnews.comDamora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Bumped Up to "Hold" by Wall Street ZenNovember 8, 2026 | americanbankingnews.comDamora Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 5, 2026 | marketscreener.comMDamora Therapeutics to Present New Preclinical Data Highlighting Potentially Best-in-Class Pan-Mutant Activity of DMR-001 in Mutant Calreticulin (mutCALR)-driven ...November 4, 2026 | markets.businessinsider.comDamora Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate HighlightsNovember 4, 2026 | globenewswire.comSee More Headlines DMRA Stock Analysis - Frequently Asked Questions How have DMRA shares performed this year? Damora Therapeutics, Inc. Common Stock's stock was trading at $23.01 at the beginning of 2026. Since then, DMRA shares have decreased by 4.2% and is now trading at $22.05. How were Damora Therapeutics, Inc. Common Stock's earnings last quarter? Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) released its quarterly earnings results on Wednesday, November, 4th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.12. When did Damora Therapeutics, Inc. Common Stock's stock split? Damora Therapeutics, Inc. Common Stock shares reverse split before market open on Friday, August 30th 2024.The 1-25 reverse split was announced on Wednesday, August 28th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Damora Therapeutics, Inc. Common Stock? Shares of DMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Damora Therapeutics, Inc. Common Stock own? Based on aggregate information from My MarketBeat watchlists, some other companies that Damora Therapeutics, Inc. Common Stock investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Tesla (TSLA), Alibaba Group (BABA), Joby Aviation (JOBY), Pinterest (PINS) and Archer Aviation (ACHR). Company Calendar Last Earnings11/04/2026Today11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (12m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 DMRA's financial health is in the Green zone, according to TradeSmith. DMRA has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:DMRA Previous SymbolNASDAQ:GLTO CIK1800315 Webgalecto.com Phone45-7070-5210FaxN/AEmployees40Year Founded2011Price Target and Rating Average Price Target for Damora Therapeutics, Inc. Common Stock$46.38 High Price Target$59.00 Low Price Target$40.00 Potential Upside/Downside+110.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($1.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$209.84 million Net MarginsN/A Pretax MarginN/A Return on Equity-122.16% Return on Assets-62.32% Debt Debt-to-Equity RatioN/A Current Ratio14.80 Quick Ratio14.80 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.91 per share Price / Book3.73Miscellaneous Outstanding Shares61,905,000Free Float61,657,000Market Cap$1.37 billion OptionableNo Data Beta1.52 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:DMRA) was last updated on 11/12/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredElon wants to move AI off the planet. Amazon isn't ready.What if the next AI race isn't on Earth? Tim Bohen's Mission X presentation explores Elon Musk's idea of movin...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Damora Therapeutics, Inc. Common Stock Please log in to your account or sign up in order to add this asset to your watchlist. Share Damora Therapeutics, Inc. Common Stock With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DMRA Stock Alerts